Federal Project Grant Award Summary

The Defense Health Agency (DHA) awarded a $559,997 Project Grant to The University of Texas MD Anderson Cancer Center for research on novel immunotherapeutic targeting of Fc Epsilon Receptor II/CD23 for CD23-positive hematologic and solid tumor malignancies. The award, issued September 1, 2026, with completion targeted for August 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This research initiative supports the DHA's mission to advance biomedical solutions addressing Service Member health through investigator-initiated basic and applied research in oncology.

The grant funds MD Anderson's research and development activities focused on designing and evaluating immunotherapeutic approaches targeting CD23-expressing malignancies. As a National Cancer Institute-designated Comprehensive Cancer Center and a major recipient of federal oncology research funding, MD Anderson will conduct the preclinical and translational research necessary to advance this immunotherapy platform toward clinical application. The two-year funding period aligns with the program's typical three- to four-year award cycle, supporting the scientific investigation, biomarker discovery, and efficacy evaluation activities required to validate this novel therapeutic target in hematologic and solid tumor contexts.